ACR 2022 Tweet by Olga Petryna
Tweet
Related Content
Podcast
Every day, every month, rheumatology publishes news and reports on JAK inhibitors, IL-17s, IL-23s, lupus, myositis, and scleroderma – all which could change how you practice dermatology. I'm Jack Cush from RheumNow, and This is Derm on RheumNow.
This month’s podcast will Scratch the surface and…
The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – Features Dr. Jack Cush, Editor at RheumNow.com.Every day, every month, rheumatology publishes news and reports on JAK inhibitors, IL-17s, IL-23s, lupus, myositis, and scleroderma – all which could…
Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and tolerable. This clinical trial done in China enrolled 548 active r-axSpA patients were enrolled in a phase…
